Samjin Pharmaceuticals Co (005500) Fair Value & Analysis
Healthcare · KR · Market cap 225B KRW
Fair value as of: Jul 22, 2026
From 23 valuation models · updated 19 days ago
Fair value updated Jul 22, 2026, revised from 30,402 KRW to 29,441 KRW (−3.2%) since Jun 25, 2026. Share price +0.5% over the past month.
A solid business, screening 60% undervalued on our models.
What matters now
- The price is below even our cautious bear case (20,261 KRW). The market is more pessimistic than our downside scenario.
- Solid quality (58/100) at a price below fair value, the discount is the argument here, not the business quality.
- A fairly wide model range (20,261 KRW to 40,577 KRW) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.
How to read this chart
60‑month range 15,569 KRW – 24,700 KRW · fair‑value band 20,261 KRW – 40,577 KRW · the 18,370 KRW price screens below the 29,441 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 22, 2026.
Analysis
Samjin Pharmaceuticals Co (005500) currently trades at 18,370 KRW, while our model-based Fair Value estimate is 29,441 KRW, implying the stock looks roughly 60.3% undervalued today. The Quality Score stands at 58/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Samjin Pharmaceuticals Co generated revenue of 254B KRW at a net margin of 16.2%. Revenue grew 1.9% year over year. It earns a return on equity of 20.3%. Net debt stands at 122B KRW. Fundamentals as of Jul 22, 2026
Our scenario range runs from 20,261 KRW (bear case) to 40,577 KRW (bull case); at 18,370 KRW, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 29% below its 52-week high and 8% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 60%, 005500 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 23 models by family
Widest divergence: Growth Earnings (34,456 KRW) versus Growth DCF (11,574 KRW). Highest evidence: Growth DCF (80).
Notify me when 005500 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 52 · Market factors (momentum, volatility) 40
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Samjin Pharmaceuticals Co., Ltd. manufactures and sells medicine. It offers medicine in oral, drop, and injecting forms.
Full company description
Samjin Pharmaceuticals Co., Ltd. manufactures and sells medicine. It offers medicine in oral, drop, and injecting forms. The company provides over-the-counter medicines, such as Gevorin, an anti-infalammatory pain killer; Trestan, an appetite stimulant; Flaris, an anti-thrombotic agent; and Nutilin, a brain function improvement agent, as well as medicine for treatment of chronic diseases. It also develops SA001, which is in Phase II clinical trial for the treatment for dry eye syndrome and Sjogren syndrome; SJP1804 medicine that is Phase I clinical trial to treat macular degeneration; and SJP1604, which is in Phase I clinical trial for cancer; SJP1901 and SJP1902 for cancer treatment; SJP 1801 to treat Alzheimer's and Parkinson's disease; SJP006, an anti-viral product; and SJP003 for treatment of diabetes. In addition, the company's preclinical product is SJP1602 for the treatment of cancer. Samjin Pharmaceuticals Co., Ltd. was founded in 1968 and is headquartered in Seoul, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Samjin Pharmaceuticals Co reported revenue of 309B KRW in FY2025 versus 250B KRW in FY2021, a compound +5.4%/yr. Reported net income was 24.2B KRW in FY2025, compounding −4.0%/yr from FY2021.
Watch 005500: get an alert when its fair value changes →
Peer Group
Drug Manufacturers - Specialty & Generic · 623 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.19 | ¥25.94 | -51% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,933 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹7,316 | ₹1,943 | -73% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,763 | ₹1,329 | -72% |
| PharmaEssentia Corporation 6446 | 1,285 TWD | 221.01 TWD | -83% |
| Cipla Limited CIPLA | ₹1,439 | ₹1,001 | -30% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,151 | ₹703.32 | -39% |
| Lupin Limited LUPIN | ₹2,443 | ₹2,477 | +1% |
| Mankind Pharma Limited MANKIND | ₹2,484 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,211 | ₹874.79 | -28% |
Compare Samjin Pharmaceuticals Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Samjin Pharmaceuticals Co (005500) overvalued or undervalued?
What is the fair value of 005500?
What is the quality score of 005500?
What is the revenue of Samjin Pharmaceuticals Co (005500)?
What is the net profit margin of 005500?
Does Samjin Pharmaceuticals Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Samjin Pharmaceuticals Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.